Alnylam Pharmaceuticals Hits 52-Week Low at USD 277.02

Alnylam Pharmaceuticals, Inc. has reached a significant milestone by touching a new 52-week low of USD 277.02 on June 16, 2026. This marks a notable decline in the stock's performance, especially when compared to its 52-week high of USD 495.31. Despite this recent downturn, Alnylam Pharmaceuticals has demonstrated a robust one-year performance, boasting an impressive increase of 83.68%, significantly outpacing the S&P 500's performance of 24.5%. The company operates within the Pharmaceuticals & Biotechnology industry and holds a market capitalization of USD 42,089 million, categorizing it as a mid-cap stock. Financial metrics reveal a price-to-earnings (P/E) ratio of 118.00, indicating a premium valuation relative to earnings. Additionally, the company maintains a return on equity of 45.14%, showcasing its efficiency in generating profits from shareholders' equity. However, it is noteworthy that Alnylam Pharmaceuticals does not offer a dividend yield, and its debt-to-equity ratio stands at -0.21, reflecting a unique financial structure.